Associate Members

  • GBMA
  • MOPI
Mexican Association of Generic Medicines Read More
Generic and Biosimilar Medicines Association (Australia) Read More
Malaysian Organisation of Pharmaceutical Industries Read More
Brazilian Generic Medicine Drugmakers Association Read More



In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association (IGBA) to reflect the evolving nature of the industry.


Vision and Mission

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.



  • IGBA Joins ICH and Welcomes the Positive Vote of the General Assembly

    Geneva, Switzerland (June 15, 2016) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to accept the IGBA as an Assembly Member of the International Council for Harmonisation of Technical Requirements Read More
  • Generic, Biosimilar and Value Added Medicines Industry Leaders Join Forces to Drive Access to Medicines Agenda

    Dubrovnik, 9 June 2016 – During the next two days, the key pharmaceutical industry leaders from the generic, biosimilar and value added medicines industries will meet in Dubrovnik to foster international partnership, cooperation and dialogue and discuss the most recent challenges Read More
  • IGBA commentary on FDA’s Draft Guidance on Labeling for Biosimilar Products

    Brussels, June 3, 2016 – IGBA thanks the Agency’s for providing an opportunity to comment on the Agency’s Draft Guidance on Labeling for Biosimilar Products (Docket No. FDA-2016-D-0643-0001). IGBA’s position is aligned with the key comments of the Biosimilar Medicines Group, Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8

Joint 22nd Medicines for Europe and 19th IGBA Annual Conference

18th Annual IGPA Conference

17th Annual IGPA Conference

Contact Info


Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.